Schering building diabetes presence de Novo: Prandin and insulin co-promotions with Novo Nordisk.
Executive Summary
SCHERING ENTERING DIABETES MARKET VIA NOVO PRANDIN, INSULIN LINE copromotion agreement announced by the two firms Jan. 28. The two companies signed a multi-year agreement to copromote Novo Nordisk's recently approved type 2 diabetes agent Prandin (repaglinide), along with Novo's full range of insulin products and devices. Prandin was approved Dec. 22 for oral treatment of type 2 diabetes as monotherapy or in combination with Bristol-Myers Squibb's Glucophage (metformin). At that time, Novo said that it would launch the product in the spring after finding a marketing partner ("The Pink Sheet" Jan. 5, p. 15).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth